Clinical Trial Update: Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial [Phase 2]

View source ↗

Summary

MD Anderson Cancer Center is conducting a Phase 2 trial (MolecularPCR) to optimize adjunct systemic therapy in early-stage HER2-positive and related breast canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 2 | Status: ACTIVE_NOT_RECRUITING